Informed by a community engagement process, we have developed a pragmatic, open-label, hybrid feasibility-implementation study of Group Psilocybin-Assisted Therapy (GPAT) for post-traumatic stress disorder (PTSD). As psychedelic-assisted therapies begin to enter the broader mental health arena, engaging communities in the design of research and care models i...
The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of methamphetamine use disorder (MUD). Participants can expect to be actively engaged in the study for up to 26 weeks. The objective of ...
BACKGROUND AND AIMS: Australia recently down-scheduled and authorised psychedelic-assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness. While service leaders and clinicians are ...
PURPOSE: The purpose of this review is to evaluate which psychedelics have the most efficacy data to support their use in the treatment of posttraumatic stress disorder (PTSD). This review also aims to assess safety data and concerns related to psychedelic therapies and identify demographic characteristics that may influence clinical outcomes. SUMMARY: A sys...
Background: As public and scientific interest in psychedelics grows, unsupervised use for health purposes is increasing. In the U.S., past-year hallucinogen use nearly doubled from 2015 to 2023. Many individuals report self-treating physical or psychological symptoms without medical supervision using psychedelics-a practice termed self-medication. Despite th...
Psilocybin, a naturally occurring tryptamine alkaloid found in over 200 species of fungi, has emerged as a focal point in the modern revival of psychedelic science. Once relegated to the margins of psychopharmacology due to its association with counterculture and strict legal restrictions, psilocybin is now undergoing a scientific renaissance. This transform...
Clinicians and researchers are showing increased interest in psychedelic-assisted therapy for patients who don't show improvement from using conventional antidepressants. This updated review integrates recent developments, including data on lesser-studied compounds like DMT and 5-MeO-DMT, findings from large clinical trials, and evolving regulatory landscape...
BackgroundSince 2006 chocolate containing psilocin is circulating in The Netherlands. Psilocin is a psychoactive substance derived from psychedelic mushrooms and known to be hard drugs. Consuming psilocin can cause symptoms such as hallucinations, fear and panic attacks and sympathomimetic effects. These effects can last for approximately 6 hours.Case descri...
AbstractBackground Psilocybin is the main psychoactive component of a naturally occurring psychedelic organism commonly referred to as "magic mushrooms." Existing literature demonstrates beneficial neurologic effects in treatment-resistant depression, cancer-associated depression and anxiety, and substance use. The evidence base for psilocybin use is on the ...
Background Psilocybin has been studied for its potential therapeutic benefits, particularly for the treatment of psychiatric disorders such as anxiety, depression, and obsessive-compulsive disorder. While more research is needed as psilocybin-assisted therapy becomes more prevalent, future pharmacists will probably be involved at some level. At present, phar...
A multidisciplinary pharmacognostic, forensic and pharmaceutical, organizational and legal, clinical and pharmacological, forensic and medical, toxicological, chemical evaluation of the irrational use of spices in smoking mixtures from the group of entheogens was carried out. An expert assessment of spices - plants and mushrooms containing psychoactive subst...
Abstract Psychoactive substances such as psilocybin and 3,4-methylenedioxy-methamphetamine (MDMA) are currently being investigated for a variety of psychiatric indications including major depressive disorder and post-traumatic stress disorder. It is critical that clinicians working in the mental health field understand the regulatory framework that balances ...
The unprecedented progress in the science and clinical investigation of psychedelic medicine will require those in healthcare leadership and the legislative policy arena to conceptualize how future reforms, policy creation, and clinical practice should occur to broaden access to these agents while simultaneously maximizing effectiveness and mitigating harm. ...
Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms. Psilocybin (4-phosphoroyloxy-N,N-dimethyltryptamine) is a hallucinogenic tryptamine that was first isolated from Psilocybe mushrooms in 1957. The objective of this Phase I clinical trial is to determine the phar...
Abstract Microcrystallopic tests for LSD, NN-diethyltryptamine, NN-dimethyltryptamine, bufotenine, psilocin, psilocybin and STP are described. The tests are recommended in conjunction with other analytical techniques if applied for the forensic identification of hallucingens.
